A Randomized Double-blind Multicenter Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants with Treatment-resistant Depression

this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 mg and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with TRD, as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to end of the 4-week double-blind treatment phase (Day 28).

You may be eligible for this study if you meet the following criteria:

• Conditions:
  depression, treatment resistant depression, TRD
• Age: - 99 Years
• Gender: All